tbuckley/cabot-search huggingface dataset:
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction
Authors: Milind Y. Desai, Anjali Owens, Kathy Wolski, Jeffrey B. Geske, Sara Saberi, Andrew Wang, Mark Sherrid, Paul C. Cremer, Neal K. Lakdawala, Albree Tower-Rader, David Fermin, Srihari S. Naidu, Nicholas G. Smedira, Hartzell Schaff, Ellen McErlean, Christina Sewell, Lana Mudarris, Zhiqun Gong, Kathy Lampl, Amy J. Sehnert, Steven E. Nissen
Journal: JAMA Cardiology (2023)

There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the short-term need for septal reduction therapy (SRT).
Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
Authors: Sharlene M. Day, James E. Udelson, Robert O. Bonow
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Multimodal metagenomic analysis reveals microbial single nucleotide variants as superior biomarkers for early detection of colorectal cancer
Authors: Wenxing Gao, Xiang Gao, Lixin Zhu, Sheng Gao, Ruicong Sun, Zhongsheng Feng, Dingfeng Wu, Zhanju Liu, Ruixin Zhu, Na Jiao
Journal: Gut Microbes (2023)

Microbial signatures show remarkable potentials in predicting colorectal cancer (CRC). This study aimed to evaluate the diagnostic powers of multimodal microbial signatures, multi-kingdom species, genes, and single-nucleotide variants (SNVs) for detecting precancerous adenomas. We performed cross-cohort analyses on whole metagenome sequencing data of 750 samples via xMarkerFinder to identify adenoma-associated microbial multimodal signatures. Our data revealed that fungal species outperformed species from other kingdoms with an area under the ROC curve (AUC) of 0.71 in distinguishing adenomas from controls. The microbial SNVs, including dark SNVs with synonymous mutations, displayed the strongest diagnostic capability with an AUC value of 0.89, sensitivity of 0.79, specificity of 0.85, and Matthews correlation coefficient (MCC) of 0.74. SNV biomarkers also exhibited outstanding performances in three independent validation cohorts (AUCs = 0.83, 0.82, 0.76; sensitivity = 1.0, 0.72, 0.93; specificity = 0.67, 0.81, 0.67, MCCs = 0.69, 0.83, 0.72) with high disease specificity for adenoma. In further support of the above results, functional analyses revealed more frequent inter-kingdom associations between bacteria and fungi, and abnormalities in quorum sensing, purine and butanoate metabolism in adenoma, which were validated in a newly recruited cohort via qRT-PCR. Therefore, these data extend our understanding of adenoma-associated multimodal alterations in the gut microbiome and provide a rationale of microbial SNVs for the early detection of CRC.
Neuropathologic and Clinical Findings in Young Contact Sport Athletes Exposed to Repetitive Head Impacts
Authors: Ann C. McKee, Jesse Mez, Bobak Abdolmohammadi, Morgane Butler, Bertrand Russell Huber, Madeline Uretsky, Katharine Babcock, Jonathan D. Cherry, Victor E. Alvarez, Brett Martin, Yorghos Tripodis, Joseph N. Palmisano, Kerry A. Cormier, Caroline A. Kubilus, Raymond Nicks, Daniel Kirsch, Ian Mahar, Lisa McHale, Christopher Nowinski, Robert C. Cantu, Robert A. Stern, Daniel Daneshvar, Lee E. Goldstein, Douglas I. Katz, Neil W. Kowall, Brigid Dwyer, Thor D. Stein, Michael L. Alosco
Journal: JAMA Neurology (2023)

Young contact sport athletes may be at risk for long-term neuropathologic disorders, including chronic traumatic encephalopathy (CTE).
Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China
Authors: Milind Y. Desai
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Mortality in Patients with Obesity and Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation: The Multicenter ECMObesity Study
Authors: Darya Rudym, Tài Pham, Craig R. Rackley, Giacomo Grasselli, Michaela Anderson, Matthew R. Baldwin, Jeremy Beitler, Cara Agerstrand, Alexis Serra, Lisle A. Winston, Desiree Bonadonna, Natalie Yip, Logan J. Emerson, Amy Dzierba, Joshua Sonett, Darryl Abrams, Niall D. Ferguson, Matthew Bacchetta, Matthieu Schmidt, Daniel Brodie, Charles Edouard Luyt, Guillaume Lebreton, Pascal Leprince, Nicolas Brechot, Guillaume Franchineau, Ania Nieszkowska, Guillaume Hekimian, Matthew Bacchetta, Darryl Abrams, Madhavi Parekh, Anil Trindade, Yoshiko Kida, Michihito Kyo, Tatsutoshi Shimatani, Nobuaki Shime, Koichi Tanigawa, Kamen Valchanov, Jo-anne Fowles, Louise Meagher, Laurent Papazian, Sami Hraiech, Jean Marie Forel, Rachael Parke, Lianne McCarthy, Eileen Gilder, Alastair McGeorge, Sophie Pierard, Luc-Marie Jacquet, Olivier Van Caenegem, Priya Nair, Claire Reynolds, Paul Forrest, Chan Wai Ming, Harriet Kong, Matt Harmon, Lilia Bouadma, Jean Francois Timsit, Romain Sonneville, Hervé Dupont, Joseph Nader, Marion Wasilewski, David Gilles, Faouzi Trojette, Mona Moubarak, Thierry Caus, Espedito Faraone, Roger Smith
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Patients with obesity are at increased risk for developing acute respiratory distress syndrome (ARDS). Some centers consider obesity a relative contraindication to receiving extracorporeal membrane oxygenation (ECMO) support, despite growing implementation of ECMO for ARDS in the general population.
Error in Supplement 2
Journal: JAMA Network Open (2023)

Manuel M. Montero-Odasso, MD, PhD; Nellie Kamkar, MSc; Frederico Pieruccini-Faria, PhD; Abdelhady Osman, MSc; Yanina Sarquis-Adamson, PhD; Jacqueline Close, MBBS, MD; David B. Hogan, MD; Susan Winifred Hunter, PT, PhD; Rose Anne Kenny, MBBS, PhD; Lewis A. Lipsitz, MD; Stephen R. Lord, PhD; Kenneth M. Madden, MD, MSc; Mirko Petrovic, MD, PhD; Jesper Ryg, MD, PhD; Mark Speechley, PhD; Munira Sultana, PhD; Maw Pin Tan, BMBS, MD; N. van der Velde, MD, PhD; Joe Verghese, MBBS, MS; Tahir Masud, MBBS, MSc; Task Force on Global Guidelines for Falls in Older Adults; Mirko Petrovic; Alice Nieuwboer; Ellen Vlaeyen; Koen Milisen; Jesper Ryg; Rose Anne Kenny; Robert Bourke; Sirpa Hartikainen; Tischa Van der Cammen; Nathalie Van der Velde; Tahir Masud; Chris Todd; Finbarr C. Martin; David R. Marsh; Sallie Lamb; James Frith; Pip Logan; Dawn Skelton; Hubert Blain; Cedric Anweiller; Ellen Freiberger; Clemens Becker; Matteo Cesari; Alvaro Casas-Herrero; Javier Perez Jara; Christina Alonzo Bouzòn; Ana-Karim Welmer; Stephanie Birnghebuam ; Reto Kressig; Manuel Montero-Odasso; Mark Speechley; Bill McIlroy; Susan Hunter; Richard Camicioli; Kenneth Madden; Mireille Norris; Jennifer Watt; Louise Mallet; David B. Hogan; Joe Verghese; Ervin Sejdic; Luigi Ferrucci; Lewis Lipsitz; David A. Ganz; Neil B. Alexander; Fabiana Giber; Marcelo Schapira; Ricardo Jauregui; Felipe Melgar-Cuellar; Daniela Cristina Carvalho de Abreu; Roberto Alves Lourenço; Monica Pierrucini; Alejandro Ceriani; Pedro Marín-Larraín ; Homero Gac Espinola; José Fernando Gómez-Montes; Carlos Alberto Cano-Gutierrez; Xinia Ramirez Ulate; José Ernesto Picado Ovares; Patricio Gabriel Buendia; Susana Lucia Tito; Diego Martínez Padilla; Sara G. Aguilar-Navarro; Alberto Mimenza ; Rogelio Moctezum; Alberto Avila-Funes ; Luis Miguel Gutiérrez-Robledo ; Luis Manuel Cornejo Alemán; Edgar Aguilera Caona; Juan Carlos Carbajal ; José F. Parodi; Aldo Sgaravatti; Stephen Lord; Cathie Sherrington; Cathy Said; Ian Cameron; Meg Morris; Gustavo Duque; Jacqueline Close; Ngaire Kerse; Maw Pin Tan; Leilei Duan; Ryota Sakurai; Chek Hooi Wong; Hossein Negahban; Chang Won Won; Jeffrey Hausdorff; Sebastiana Kalula; Olive Kobusingye
Protective Factors and the Pathogenesis of Complications in Diabetes
Authors: Marc Gregory Yu, Daniel Gordin, Jialin Fu, Kyoungmin Park, Qian Li, George Liang King
Journal: Endocrine Reviews (2023)

Chronic complications of diabetes are due to myriad disorders of numerous metabolic pathways that are responsible for most of the morbidity and mortality associated with the disease. Traditionally, diabetes complications are divided into those of microvascular and macrovascular origin. We suggest revising this antiquated classification into diabetes complications of vascular, parenchymal, and hybrid (both vascular and parenchymal) tissue origin, since the profile of diabetes complications ranges from those involving only vascular tissues to those involving mostly parenchymal organs. A major paradigm shift has occurred in recent years regarding the pathogenesis of diabetes complications, in which the focus has shifted from studies on risks to those on the interplay between risk and protective factors. While risk factors are clearly important for the development of chronic complications in diabetes, recent studies have established that protective factors are equally significant in modulating the development and severity of diabetes complications. These protective responses may help explain the differential severity of complications, and even the lack of pathologies, in some tissues. Nevertheless, despite the growing number of studies on this field, comprehensive reviews on protective factors and their mechanisms of action are not available. This review thus focused on the clinical, biochemical, and molecular mechanisms that support the idea of endogenous protective factors, and their roles in the initiation and progression of chronic complications in diabetes. In addition, this review also aimed to identify the main needs of this field for future studies.
Multifunctional nanoadjuvant-driven microenvironment modulation for enhanced photothermal immunotherapy in breast cancer
Authors: Ge Li, Jingbo Zhang, Shixin Zhang, Lesheng Teng, Fengying Sun
Journal: Journal of Controlled Release (2023)

Intracellular redox imbalance, achieved by exploiting the tumor microenvironment (TME), has emerged as a promising strategy for cancer therapy. In this study, we developed a multifunctional nanoadjuvant, termed GITFe/Z-HA, by modified a metal-organic backbone Fe/ZIF-8 with hyaluronic acid (HA) targeting. The nanocarriers were loaded with glucose oxidase (Gox), neoindocyanine green (IR820) and tilazamine (TPZ). This design aimed to achieve a cascade reaction within tumor cells, mediated by Gox, Fe3+, and IR820, which consumes intrinsic glucose and oxygen, leading to an elevated production of reactive oxygen species (ROS). This cascade reaction creates a hypoxic environment conducive for TPZ to exert its therapeutic action. Consequently, the combination of photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy demonstrates a good synergistic effect. Moreover, the imbalanced ROS/glutathione (GSH) induced by this treatment approach, along with PTT, promote immunogenic cell death (ICD). This ICD triggers the release of damage-related molecular patterns and CD8+ lymphocyte infiltration sensitizes the immune checkpoint blockade (αPD-L1) response, thereby eliciting a systemic anti-tumor immune response. Collectively, this comprehensive treatment regimen, driven by environmentally stimulated multiple pathways, overcomes the limitations of single therapeutic modalities, thereby improving tumor outcomes. Additionally, these findings provide valuable insights for strategies aimed at modulating the tumor immune microenvironment.
Targeting helminths: The expanding world of type 2 immune effector mechanisms
Authors: Rick M. Maizels, William C. Gause
Journal: The Journal of Experimental Medicine (2023)

In this new review, Rick Maizels and Bill Gause summarize how type 2 immune responses combat helminth parasites through novel mechanisms, coordinating multiple innate and adaptive cell and molecular players that can eliminate infection and repair-resultant tissue damage.
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial
Authors: Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Takuya Oyakawa, Michihisa Umetsu, Daijirou Akamatsu, Yuji Nishimoto, Yukihito Sato, Takuma Takada, Kentaro Jujo, Yuichiro Minami, Yoshito Ogihara, Kaoru Dohi, Masashi Fujita, Tatsuya Nishikawa, Nobutaka Ikeda, Go Hashimoto, Kazunori Otsui, Kenta Mori, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Makoto Mo, Yusuke Yoshikawa, Takeshi Kimura
Journal: Circulation (2023)

BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned patients with cancer with isolated distal deep vein thrombosis, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary end point was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary end point was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Haemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary end point. RESULTS: From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of deep vein thrombosis at baseline. The primary end point of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03–0.44). The major secondary end point of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75–2.41). The prespecified subgroups did not affect the estimates on the primary end point. CONCLUSIONS: In patients with cancer with isolated distal deep vein thrombosis, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03895502.
Identification of Human Ventricular Tachycardia Demarcated by Fixed Lines of Conduction Block in a 3-Dimensional Hyperboloid Circuit
Authors: Takuro Nishimura, Nathan Shatz, J. Peter Weiss, Michael Zawaneh, Rong Bai, Andrew D. Beaser, Gaurav A. Upadhyay, Zaid A. Aziz, Hemal M. Nayak, Dalise Y. Shatz, Shinsuke Miyazaki, Masahiko Goya, Tetsuo Sasano, Wilber Su, Michael Raiman, Roderick Tung
Journal: Circulation (2023)

The circuit boundaries for reentrant ventricular tachycardia (VT) have been historically conceptualized within a 2-dimensional (2D) construct, with their fixed or functional nature unresolved. This study aimed to examine the correlation between localized lines of conduction block (LOB) evident during baseline rhythm with lateral isthmus boundaries that 3-dimensionally constrain the VT isthmus as a hyperboloid structure.A total of 175 VT activation maps were correlated with isochronal late activation maps during baseline rhythm in 106 patients who underwent catheter ablation for scar-related VT from 3 centers (42% nonischemic cardiomyopathy). An overt LOB was defined by a deceleration zone with split potentials (≥20 ms isoelectric segment) during baseline rhythm. A novel application of pacing within deceleration zone (≥600 ms) was implemented to unmask a concealed LOB not evident during baseline rhythm. LOB identified during baseline rhythm or pacing were correlated with isthmus boundaries during VT.Among 202 deceleration zones analyzed during baseline rhythm, an overt LOB was evident in 47%. When differential pacing was performed in 38 deceleration zones without overt LOB, an underlying concealed LOB was exposed in 84%. In 152 VT activation maps (2D=53, 3-dimensional [3D]=99), 69% of lateral boundaries colocalized with an LOB in 2D activation patterns, and the depth boundary during 3D VT colocalized with an LOB in 79%. In VT circuits with isthmus regions that colocalized with a U-shaped LOB (n=28), the boundary invariably served as both lateral boundaries in 2D and 3D. Overall, 74% of isthmus boundaries were identifiable as fixed LOB during baseline rhythm or differential pacing.The majority of VT circuit boundaries can be identified as fixed LOB from intrinsic or paced activation during sinus rhythm. Analysis of activation while pacing within the scar substrate is a novel technique that may unmask concealed LOB, previously interpreted to be functional in nature. An LOB from the perspective of a myocardial surface is frequently associated with intramural conduction, supporting the existence of a 3D hyperboloid VT circuit structure. Catheter ablation may be simplified to targeting both sides around an identified LOB during sinus rhythm.
Decellularized Scaffolds with Double‐Layer Aligned Microchannels Induce the Oriented Growth of Bladder Smooth Muscle Cells: Toward Urethral and Ureteral Reconstruction
Authors: Quhan Cheng, Linli Zhang, Jingai Zhang, Xin Zhou, Boyu Wu, Dezheng Wang, Tingting Wei, Muhammad Shafiq, Shengbin Li, Dengke Zhi, Yong Guan, Kai Wang, Deling Kong
Journal: Advanced Healthcare Materials (2023)

There is a great clinical need for regenerating urinary tissue. Native urethras and ureters have bidirectional aligned smooth muscle cells (SMCs) layers, which plays a pivotal role in micturition and transporting urine and inhibiting reflux. Thus far, urinary scaffolds have not been designed to induce the native-mimicking aligned arrangement of SMCs. In this study, a tubular decellularized extracellular matrix (dECM) with an intact internal layer and bidirectional aligned microchannels in the tubular wall, which is realized by the subcutaneous implantation of a template, followed by the removal of the template, and decellularization, is engineered. The dense and intact internal layer effectively increases the leakage pressure of the tubular dECM scaffolds. Rat-derived dECM scaffolds with three different sizes of microchannels are fabricated by tailoring the fiber diameter of the templates. The rat-derived dECM scaffolds exhibiting microchannels of ≈65 µm show suitable mechanical properties, good ability to induce the bidirectional alignment and growth of human bladder SMCs, and elevated higher functional protein expression in vitro. These data indicate that rat-derived tubular dECM scaffolds manifesting double-layer aligned microchannels may be promising candidates to induce the native-mimicking regeneration of SMCs in urethra and ureter reconstruction.
Separating Actionable From Incidental Findings—Imperative for Meaningful Clinical Outcomes
Authors: Sucharita Kher, Arnold Cheung, Lindsay S. Baron
Journal: JAMA Internal Medicine (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Estimated Lifetime Gained With Cancer Screening Tests
Authors: Michael Bretthauer, Paulina Wieszczy, Magnus Løberg, Michal F. Kaminski, Tarjei Fiskergård Werner, Lise M. Helsingen, Yuichi Mori, Øyvind Holme, Hans-Olov Adami, Mette Kalager
Journal: JAMA Internal Medicine (2023)

Cancer screening tests are promoted to save life by increasing longevity, but it is unknown whether people will live longer with commonly used cancer screening tests.
Cardioprotective and Anti-Inflammatory Effects of FAM3D in Myocardial Ischemia-Reperfusion Injury
Authors: James Rhee, Rebecca Freeman, Kangsan Roh, Margaret Lyons, Chunyang Xiao, Daniel Zlotoff, Ashish Yeri, Haobo Li, Justin Guerra, J. Sawalla Guseh, Alexandra Kuznetsov, Nicholas Houstis, Jason Roh, Federico Damilano, Xiaojun Liu, Michael Silverman, Raymond Kwong, Saumya Das, Anthony Rosenzweig
Journal: Circulation Research (2023)